Merck nears deal for flu-prevention biotech Cidara
San Diego company’s lead drug is a potential alternative to vaccines for vulnerable patients
Related reading
Merck transforms itself through dealmaking as clock ticks on top-selling drug
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
BioNTech settles Covid-19 patent dispute with CureVac
UK’s GSK will receive $370mn and 1% of sales of some vaccines as part of the deal
Novartis weighs deal for biotech Avidity to boost drug pipeline
Shares in rare disease biotech surge 26% following approach by Swiss group
Merck’s record cancer drug sales power earnings growth
Quarterly proceeds from Keytruda top $8bn for first time
Pfizer shows hardball mettle needed to win in 2025 M&A
Pharma giant had to pay a blockbuster price to buy Metsera after the biotech prospect spurred an auction with Novo Nordisk